The Global Intravenous (IV) Therapy and Vein Access Market size is expected to reach $33. 6 billion by 2028, rising at a market growth of 5. 3% CAGR during the forecast period. Intravenous (IV) therapy is a therapeutic procedure that involves infusing liquid substances such as electrolytes, medications, nourishment, and blood-based products directly into the veins.

New York, June 23, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Intravenous Therapy and Vein Access Market Size, Share & Industry Trends Analysis Report By End User, By Application, By Type, By Regional Outlook and Forecast, 2022 - 2028" - https://www.reportlinker.com/p06283441/?utm_source=GNW The fastest approach to give fluids to different regions of the body is through IV therapy. Heart attacks, strokes, and poisoning are all treated with this medication. In such instances, the patient should receive medication as soon as possible, hence IV medication is administered. Chemotherapy treatments, antibiotics, antifungal drugs, pain relievers, immunoglobulin therapies, and blood pressure meds are among the drugs given intravenously. Intravenous treatment (IV) is a way of delivering drugs and fluids to the body through the veins. Vitamin and mineral-containing drugs are administered through an IV drip or vein injection, allowing the therapy to flow swiftly through the bloodstream. IV administration, according to the Scope, is when a patient receives substances straight into their veins using a tube called a cannula. This could be a side effect of medication or a nutrient deficiency. IV therapy is a typical way to provide dehydrated patients fluids, medicines, chemotherapeutic treatments, and blood transfusions. During IV administration, various IV equipment like IV Catheters, Infusion Pumps, Securement Devices, Administration Sets, and so on are used. IV treatment is quick to administer, easy to track, and free of gastrointestinal side effects. When compared to oral treatment, it promotes a faster immune system response and relief from chronic conditions. It has an infusion pump that controls the volume of a chemical to be supplied to the body and can be easily monitored. Over the forecast period, the global intravenous treatment and vein access devices market is expected to increase. Diabetes prevalence, rising incidence of traffic accidents, and an increase in surgical operations are projected to propel the industry forward. This industry is also being driven by rising demand for sophisticated approaches such as drug administration without needles. COVID-19 Impact COVID-19 has a positive overall influence on the IV treatment market. In patients with severe COVID-19-associated Acute Respiratory Distress Syndrome, IV treatment is administered (ARDS). The use of intravenous immunoglobulin therapy for COVID-19 ARDS, for example, was published in The Lancet Respiratory Medicine Journal on November 11, 2021, as an appealing adjuvant for the management of severe COVID-19-associated ARDS because of its ability to simultaneously modulate multiple immune compartments. As a result, the demand for IV therapy and vein access products has increased as the number of patients suffering from COVID-19-associated ARDS has increased. Market Growth Factors Increased operations and a growing geriatric population Over the previous decade, the prevalence of various chronic conditions requiring vascular access treatment has increased. Cancer, kidney failure, and heart disease, among other chronic diseases, as well as various lifestyle conditions like hypertension, diabetes, obesity, and depression, among others, necessitate critical care during hospitalization. In the next years, the increasing burden of chronic diseases like cardiovascular disease, cancer, stroke, and diabetes, combined with an aging population, generates more demand for intravenous therapy. Technological advancements Intravenous catheters (peripheral and central), accessories with safety devices, and cutting-edge infusion pumps are among the technological resources that can contribute to a safer and higher-quality intravenous treatment (IVT) practice. Because health technology is a complicated subject that produces daily reflections and discussions among the health professionals involved in the care of the patient in the Intensive Care Unit, major changes in nursing care have occurred as a result of the incorporation of new technologies, and cutting-edge infusion pumps are among the technological resources that can contribute to a safer and higher-quality intravenous treatment (IVT) practice. Market Restraining Factors Pump Manufacturing Requires Strict Regulations and concerns about complications The licensing process for new items is being slowed by more severe requirements surrounding the production and incorporation of pumps. Additionally, rising product recalls owing to manufacturing faults would slow down the adoption rate of these therapies. Fresenius Kabi, for example, recalled the Vigilant Agilia drug library and the Volumat MC Agilia infusion pump in August 2019 due to infusion alarm issues, low priority keep vein open (KVO), and other software errors. The major barriers to the industry growth are complications associated with utilizing the IV method and IV infusion products. End User Outlook Based on End User, the market is segmented into Hospitals, Ambulatory Surgical Center, and Clinics. In 2021, the Hospitals segment garnered the maximum revenue share of the Intravenous (IV) Therapy and Vein Access Market. This is due to a rise in the number of surgeries conducted compared to ambulatory surgical centers and clinics. Moreover, the growth of the segment is credited to an increase in the use of IV therapy in hospitals, which includes IV antibiotic treatment, medication for unconscious patients, drugs that cannot be administered orally, interventional radiology, anti-cancer drugs, hemodialysis, repeated blood sample drawings, and blood transfusion. The market for IV therapy and vein access devices is growing thanks to technological advancements and hospital investments. Application Outlook Based on Application, the market is segmented into Medication Administration, Blood Based Products, Nutrition & Buffer Solution, and Volume Expander. The Volume Expander segment obtained a significant revenue share of the Intravenous (IV) Therapy and Vein Access Market in 2021. For a minority of fluid-sensitive athletes, IV fluid may be useful; however, this should be reserved for high-level athletes with strong histories of symptoms in well-monitored situations. Some athletes may benefit from using volume expanders. In contests controlled by the World Anti-Doping Agency, IV fluids and plasma binders are prohibited. For the vast majority of athletes, routine IV therapy is not the best option. Type Outlook Based on Type, the market is segmented into Intravenous Catheters, Infusion Pumps, Hypodermic Needles, Implantable Ports, and Others. In 2021, the Intravenous Catheters segment procured the largest revenue share of the Intravenous (IV) Therapy and Vein Access Market. This is due to the increased usage of IV catheters during surgical procedures for IV therapies and during the transfer of blood, medicine, and other nutrients to various parts of the body. An intravenous catheter is a tiny tube that is placed into a cavity or lumen in the body. Intravenous catheters are a type of intravenous catheter that is used to deliver drugs, fluids, or other therapies straight into the bloodstream. They’re most commonly introduced into a vein in the arm, although they can also be inserted in the neck, chest, or groin. Depending on their intended purpose, intravenous catheters come in a variety of sizes and forms. Regional Outlook Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. In 2021, North America emerged as the leading region in the Intravenous (IV) Therapy and Vein Access Market by acquiring the highest revenue share of the market. The growth of the regional market can be attributed to an uptick in the pool of patient population, a rise in the prevalence of road accidents, a high rise in trauma cases, and an increase in federal investments in the development of better healthcare facilities and R&D activities. The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include B. Braun Melsungen AG, Medtronic PLC, Terumo Corporation, Fresenius SE & Co. KGaA, Cardinal Health, Inc., Pfizer, Inc., Teleflex, Inc., Baxter International, Inc., Smiths Group PLC, and AngioDynamics, Inc. Strategies Deployed in Intravenous (IV) Therapy and Vein Access Market Mar-2022: Fresenius Kabi signed an agreement to acquire Fresenius Kabi, a global healthcare company. This acquisition aimed to integrate Ivenix’s enhanced infusion system within Fresenius Kabi’s intravenous fluids and infusion therapy portfolio would bring a broad offering of blended products to U.S. hospitals. Dec-2021: Baxter came into a partnership with Hillrom, an American medical technology provider. Through this partnership, the companies aimed to integrate two dominant Medtech enterprise in a shared vision for changing healthcare and improving patient care across the world. May-2021: Smiths Medical came into a partnership with Ivenix, a medical technology company. Through this partnership, the companies aimed to provide a broad offering of infusion management solutions. Additionally, Smiths Medical would deliver a strategic investment for the long-term partnership that aims to revolutionize blended management and enhance patient health while meeting the demands of a healthcare supplier. Apr-2021: B. Braun Medical introduced Peripheral Advantage, a new program that improves patients’ experience with peripheral intravenous therapy. The program integrates clinical direction, data-driven intuition, and improved tools to authorize nurses to attain first-stick success and assist avoid various complexity related to peripheral IV therapy. Jul-2019: Baxter received a U.S. Food and Drug Administration (FDA) approval of Myxredlin. The approval allows instant insulin for IV infusion in the hospital and other keen care settings and features an extensive shelf life of 30 days at room temperature or 24 months if refrigerated in the original package to secure from light. Scope of the Study Market Segments covered in the Report: By End User • Hospitals • Ambulatory Surgical Center • Clinics By Application • Medication Administration • Blood Based Products • Nutrition & Buffer Solution • Volume Expander By Type • Intravenous Catheters • Infusion Pumps • Hypodermic Needles • Implantable Ports • Others By Geography • North America o US o Canada o Mexico o Rest of North America • Europe o Germany o UK o France o Russia o Spain o Italy o Rest of Europe • Asia Pacific o China o Japan o India o South Korea o Singapore o Malaysia o Rest of Asia Pacific • LAMEA o Brazil o Argentina o UAE o Saudi Arabia o South Africa o Nigeria o Rest of LAMEA Companies Profiled • B. Braun Melsungen AG • Medtronic PLC • Terumo Corporation • Fresenius SE & Co. KGaA • Cardinal Health, Inc. • Pfizer, Inc. • Teleflex, Inc. • Baxter International, Inc. • Smiths Group PLC • AngioDynamics, Inc. Unique Offerings • Exhaustive coverage • Highest number of market tables and figures • Subscription based model available • Guaranteed best price • Assured post sales research support with 10% customization free Read the full report: https://www.reportlinker.com/p06283441/?utm_source=GNW About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________

The synthetic opioid, in all its forms, is the No. 1 drug being distributed in Charlotte, according to a CMPD narcotics officer.

The deal marks one of Amazon's most high-profile pushes into health care to date.

As Amazon extends its tentacles further into the healthcare sector, many people are expressing their concerns about the One Medical deal.

Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) stocks have bucked the bear market trend so far this year, gaining 6% and 20% respectively, compared to the S&P 500's loss of more than 17%. Analysts at Morgan Stanley recently noted that obesity has the potential to become the next blockbuster pharma category, reaching a value of $54 billion in 2030. The main reason for that projection is that treatment trends are showing more of a focus on upstream causes of diabetes and cardiovascular disease, rather than on treating the resulting diseases.

The new COVID-19 variants are more transmissible than ever, but how different do symptoms look compared to a year ago?

Not everyone should take Pfizer's COVID-19 antiviral drug, doctors say

The FDA bestows a Fast Track designation to Olema's (OLMA) novel pipeline candidate, OP-1250, for the treatment of ER+/HER2- metastatic breast cancer. Stock up.

Alzheimer's disease and other forms of cognitive decline present a devastating worldwide problem—and it's a condition that is steadily on the rise. According to Alzheimer's Disease International (ADI), there were over 55 million people living with dementia across the world in 2020, and that number is projected to reach 139 million by 2050. There is no known cure for dementia, making it essential to look for early symptoms of the disease in order to access treatment. The benefits of an early diag

The 6-year-old was bitten while at the Bluestem Prairie Open Space near Colorado Springs on July 5 and died Monday.

U.S. COVID cases and hospitalizations are rising again and are now trending at the highest level seen this summer so far, as the BA.5 omicron subvariant becomes dominant.

White House pandemic response coordinator Dr. Ashish Jha delivered a grim message on Friday about the ever-evolving coronavirus pathogen that the Centers for Disease Control and Prevention estimates has infected more than 140 million Americans, including President Biden.

Amazon's health care expansion plans, including its $3.9 billion acquisition of One Medical, shook health care stocks.

People may not normally have noticed an 11-year-old girl, but no one could overlook when her belly grew fatter and fatter, Amelia Robinson writes.

A recent study has found that Bay Area residents of Asian descent were more likely to be hospitalized with COVID-19 than any other racial or ethnic group in the area in 2020. The research, co-authored by a University of California, San Francisco, researcher and published in the Journal of Racial and Ethnic Health Disparities on Tuesday, noted that the heightened risk among Asians cannot be fully explained by socioeconomic factors or pre-existing medical conditions. While the study also included Black, Hispanic and white residents, Asians were the only racial group whose age, income, health insurance status and medical comorbidities did not fully account for their higher risk of hospitalization.

The 67-year-old woman was airlifted from Portland in the US to Chennai in India for surgery.

A Chinese court has overruled a rare legal challenge brought by an unmarried Beijing woman seeking the right to freeze her eggs. The Chaoyang Intermediate People's Court in Beijing said in a judgment that the hospital did not violate the woman's rights in denying her access to freeze her eggs. Unmarried women who choose to have children have struggled to access public benefits like maternity leave or coverage for prenatal exams.

If you're suffering from arthritis, you're one of approximately 58.5 million people in the United States who deals with this disease (or 1 in every 4 adults). It is a leading cause of work disability, with more than half of U.S. adults (57.3%) with arthritis of working age between 18 to 64 years old.The good news is that there are ways to reduce its symptoms, which include pain, aching, stiffness, and swelling in or around the joints. Some examples are taking supplements, watching what you eat,

J&J (JNJ) and Novartis (NVS) report Q2 earnings. GSK completes separation of its Consumer Healthcare (CHC) segment.

People who are vaccinated against COVID-19, such as Biden, can still get infected. That doesn't mean the vaccine doesn't work.

10,000 may be an arbitrary number, but the daily step goal has helped improve my mental and physical health